J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 1138KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 88(9): 1109-1112, 1987

Report on the annual meeting

EXPERIMENTAL AND CLINICAL STUDY ON CHEMO-ENDOCRINE THERAPY FOR GASTRIC CARCINOMA

*) Dept. of Surgery, National Kanagawa Hospital, Hadano, Japan
**) Res. Center Mitsubishi Chem. Ind., Yokohama, Japan
***) Dept. of Surgery, School of Medicine, Keio University, Tokyo, Japan

Katsuhiko Nohga*), Takao Katsumata*), Shimao Fukai*), Ko-ichi Ishiwata*), Kazuhiro Nagaike**), Osahiko Abe***)

In order to clarify the action of antiestrogenic agent (tamoxifen) on scirrhous carcinoma of stomach, we developed a new model of estrogen-dependent tumor in nude mice (EG I III) using human gastric cancer cells in culture.
EG I III strain was evaluated to be ER-positive by DCC method and its growth was enchanced by administration of EP hormone. Tamoxifen 2.5mg/kg was administered to EG I III tumor twice a week for 6 weeks. Mitomycin-C (MMC) 1.5mg/kg was administered once a week for 6 weeks. Tamoxifen inhibited the growth of EG I III tumor as much as MMC.
In clinical test, we applied tamoxifen to one patient with recurrence of gastric carcinoma and five patients with scirrhous carcinoma of stomach. In two patients, the favorable responce was observed as far as serum CEA level was concerned, especially one patient, suffering from ileus due to the recurrence of stomach carcinoma, improved clinically by the administration of tamoxifen.
From these results, it might be suggested that tamoxifen is a useful drug for patient with ER-positive scirrhous carcinoma of stomach.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.